Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Debt (2017 - 2023)

Historic Total Debt for Sutro Biopharma (STRO) over the last 7 years, with Q4 2023 value amounting to $4.1 million.

  • Sutro Biopharma's Total Debt fell 7504.15% to $4.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $4.1 million, marking a year-over-year decrease of 7504.15%. This contributed to the annual value of $4.1 million for FY2023, which is 7504.15% down from last year.
  • As of Q4 2023, Sutro Biopharma's Total Debt stood at $4.1 million, which was down 7504.15% from $7.1 million recorded in Q3 2023.
  • Sutro Biopharma's Total Debt's 5-year high stood at $25.3 million during Q1 2022, with a 5-year trough of $4.1 million in Q4 2023.
  • In the last 5 years, Sutro Biopharma's Total Debt had a median value of $20.8 million in 2022 and averaged $18.1 million.
  • As far as peak fluctuations go, Sutro Biopharma's Total Debt surged by 14853.18% in 2020, and later plummeted by 7504.15% in 2023.
  • Sutro Biopharma's Total Debt (Quarter) stood at $9.9 million in 2019, then skyrocketed by 148.53% to $24.5 million in 2020, then increased by 2.31% to $25.1 million in 2021, then plummeted by 35.21% to $16.3 million in 2022, then plummeted by 75.04% to $4.1 million in 2023.
  • Its Total Debt was $4.1 million in Q4 2023, compared to $7.1 million in Q3 2023 and $10.2 million in Q2 2023.